DB:IDD

Stock Analysis Report

Executive Summary

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally.

Rewards

PE ratio (13.8x) is below the German market (21.1x)

Became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of -20.3% per year for the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Innate Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IDD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.8%

IDD

1.0%

DE Biotechs

2.0%

DE Market


1 Year Return

12.8%

IDD

6.8%

DE Biotechs

15.1%

DE Market

Return vs Industry: IDD exceeded the German Biotechs industry which returned 6.2% over the past year.

Return vs Market: IDD underperformed the German Market which returned 15% over the past year.


Shareholder returns

IDDIndustryMarket
7 Day6.8%1.0%2.0%
30 Day8.6%-1.2%1.0%
90 Day34.1%7.4%3.8%
1 Year12.8%12.8%7.1%6.8%18.6%15.1%
3 Year-33.3%-33.3%48.3%46.6%16.8%6.6%
5 Year-23.3%-23.3%11.4%9.0%23.7%6.7%

Price Volatility Vs. Market

How volatile is Innate Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Innate Pharma undervalued compared to its fair value and its price relative to the market?

13.84x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IDD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IDD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IDD is good value based on its PE Ratio (13.8x) compared to the Biotechs industry average (43.8x).

PE vs Market: IDD is good value based on its PE Ratio (13.8x) compared to the German market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: IDD's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: IDD is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Innate Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-20.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDD's earnings are forecast to decline over the next 3 years (-20.3% per year).

Earnings vs Market: IDD's earnings are forecast to decline over the next 3 years (-20.3% per year).

High Growth Earnings: IDD's earnings are forecast to decline over the next 3 years.

Revenue vs Market: IDD's revenue is expected to decline over the next 3 years (-3.9% per year).

High Growth Revenue: IDD's revenue is forecast to decline over the next 3 years (-3.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDD is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Innate Pharma performed over the past 5 years?

10.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDD has high quality earnings.

Growing Profit Margin: IDD became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: IDD has become profitable over the past 5 years, growing earnings by 10.4% per year.

Accelerating Growth: IDD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IDD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: IDD's Return on Equity (17.3%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Innate Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: IDD's short term assets (€216.7M) exceed its short term liabilities (€94.5M).

Long Term Liabilities: IDD's short term assets (€216.7M) exceed its long term liabilities (€76.7M).


Debt to Equity History and Analysis

Debt Level: IDD's debt to equity ratio (1.3%) is considered satisfactory.

Reducing Debt: IDD's debt to equity ratio has reduced from 1.8% to 1.3% over the past 5 years.


Balance Sheet

Inventory Level: IDD has a low level of unsold assets or inventory.

Debt Coverage by Assets: IDD's debt is covered by short term assets (assets are 93.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDD is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: IDD is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is Innate Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate IDD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IDD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDD's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Mondher Mahjoubi (61yo)

3.2yrs

Tenure

€1,322,183

Compensation

Dr. Mondher Mahjoubi, M.D., has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016. Dr. Mahjoubi has more than 20 years of experience working in  ...


CEO Compensation Analysis

Compensation vs Market: Mondher's total compensation ($USD1.43M) is above average for companies of similar size in the German market ($USD801.26K).

Compensation vs Earnings: Mondher's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Hervé Brailly
Co-Founder & Chairman of Supervisory Board3.2yrs€150.00k1.24% 6.9m
Mondher Mahjoubi
Chairman of Executive Board & CEO3.2yrs€1.32m0.065% 360.9k
Yannis Morel
Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board4.8yrs€552.23k0.084% 462.4k
François Romagné
0yrsno datano data
Eric Vivier
Founder0yrsno data0.092% 509.8k
Marc Bonneville
0yrsno datano data
Jean Fournié
0yrsno datano data
Alessandro Moretta
0yrsno datano data
Laure-Hélène Mercier
Executive VP3.2yrsno data0.018% 97.4k
Danielle Spangler
Head of Investor Relations0yrsno datano data

4.0yrs

Average Tenure

55yo

Average Age

Experienced Management: IDD's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hervé Brailly
Co-Founder & Chairman of Supervisory Board3.2yrs€150.00k1.24% 6.9m
Patrick Langlois
Member of Supervisory Board9.8yrs€43.50k0.010% 57.1k
Maïlys Ferrere
Member of Supervisory Board2.7yrsno datano data
Gilles Brisson
Member of Supervisory Board12.6yrs€43.75k0.061% 337.2k
Jean-Yves Blay
Member of Supervisory Board2.2yrs€31.00k0.000060% 332.0
Irina Staatz-Granzer
Vice Chairman of Supervisory Board0yrs€28.75k0.032% 176.1k
Miriam Merad
Chairman of Strategic Advisory Board0yrsno datano data
Véronique Chabernaud
Member of Supervisory Board4.8yrs€28.50k0.000010% 55.3
Sebastian Amigorena
Strategic Advisory Board Member1.3yrsno datano data
Marcus Schindler
Member of Supervisory Board1.9yrsno datano data

2.9yrs

Average Tenure

58yo

Average Age

Experienced Board: IDD's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.3%.


Top Shareholders

Company Information

Innate Pharma S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innate Pharma S.A.
  • Ticker: IDD
  • Exchange: DB
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €553.341m
  • Shares outstanding: 78.88m
  • Website: https://www.innate-pharma.com

Number of Employees


Location

  • Innate Pharma S.A.
  • 117 Avenue de Luminy
  • BP 30191
  • Marseille
  • Provence-Alpes-Côte d'Azur
  • 13009
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPHENXTPA (Euronext Paris)YesCategory O Ordinary SharesFREURNov 2006
IDDDB (Deutsche Boerse AG)YesCategory O Ordinary SharesDEEURNov 2006
0EVILSE (London Stock Exchange)YesCategory O Ordinary SharesGBEURNov 2006
IPHY.FOTCPK (Pink Sheets LLC)YesCategory O Ordinary SharesUSUSDNov 2006
IPHPBATS-CHIXE (BATS 'Chi-X Europe')YesCategory O Ordinary SharesGBEURNov 2006
IPHSWX (SIX Swiss Exchange)YesCategory O Ordinary SharesCHCHFNov 2006
IPHANasdaqGM (Nasdaq Global Market)UNSP ADS EACH REPR 1 ORD SHSUSUSDOct 2015
IDDBMUN (Boerse Muenchen)UNSP ADS EACH REPR 1 ORD SHSDEEUROct 2015
IPHANasdaqGS (Nasdaq Global Select)SPON ADS EACH REP 1 ORD SHSUSUSDOct 2019
IDDAMUN (Boerse Muenchen)SPON ADS EACH REP 1 ORD SHSDEEUROct 2019

Biography

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. It also provides IPH5201, an anti-CD39 antibody and IPH5301, an anti-CD73 antibody, which is in pre-clinical stage for the treatment of immuno-oncology. In addition, the company offers IPH61, a bispecific NK cell engager that is used to create novel molecular formats to kill tumor cells through NKp46. Further, it provides Lumoxiti, a commercial-stage oncology product for treating hairy cell leukemia. Innate Pharma S.A. has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi; and a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 21:10
End of Day Share Price2020/02/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.